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Background: This study aimed to establish the maximum tolerated 
dose (MTD) of weekly bortezomib in combination with fixed stan-
dard doses of carboplatin and bevacizumab, and to estimate the effi-
cacy (response rate and progression free survival [PFS]) and safety of 
combination therapy with carboplatin, bortezomib, and bevacizumab 
as first-line therapy in patients with advanced non–small-cell lung 
cancer (NSCLC).
Methods: Patients were assigned to three dose levels of weekly 
bortezomib with the fixed standard doses of carboplatin AUC 6 and 
bevacizumab (15 mg/kg) every 3 weeks using a standard phase-I 
design. Bortezomib doses were 1.3 mg/m2, 1.6 mg/m2, and 1.8 mg/m2 
weekly on day 1 and day 8 of every 3-week cycle. A maximum of six 
cycles was administered. Patients with complete, partial response or 
stable disease were continued on single-agent bevacizumab (15 mg/
kg every 3 weeks) as maintenance therapy. In phase II, either level III 
or MTD was administered to evaluate the efficacy and safety of the 
combination in first-line treatment of advanced NSCLC.
Results: Sixteen patients were enrolled (three, four, and nine patients 
in dose level I, II, and III, respectively). There was no predefined 
dose limiting toxicity in cycle 1 in all 16 patients. The recommended 
phase-II dose is bortezomib 1.8 mg/m2 weekly on day 1 and day 8 
in combination with carboplatin AUC 6 and bevacizumab 15 mg/
kg on every 21-day cycle. Totally 9 patients were treated at the rec-
ommended phase-II dose level. The most common treatment related 
grade-3/4 toxicities during the subsequent cycles were thrombocy-
topenia (58%), lymphopenia (25%), neutropenia (12%), and diarrhea 
(25%). The grade-1/2 neuropathy was seen in 7 out of 16 patients 
(44%). The response rate, PFS, and overall survival in all patients 
were 37.5% (95%CI 13.8%–61.2%), 5.0 months (95%CI: 3.1–8.4), 
9.9 months (95% CI: 8.2–14.1), and among the 9 patients in phase-II 
portion are 44% (95%CI 15.3%–77.3%), 5.5 months (95%CI: 3.1–
2.2) and 10.9 months (95%CI: 8.0–14.1).
Conclusion: The recommended phase-II dose for this combination 
is: carboplatin AUC 6, bevacizumab 15 mg/kg on day 1 and bort-
ezomib 1.8 mg/m2 on day 1 and day 8 on every 21-day cycle. The 
regimen was very well tolerated with interesting clinical activity in 
first-line treatment of NSCLC.
Key Words: Bortezomib, Bevacizumab, Metastatic non–
small-cell lung cancer.
(J Thorac Oncol. 2012;7: 1032–1040)
Non–small-cell lung cancer (NSCLC) remains the leading cause of cancer deaths in the United States.1 The plat-
inum-based, palliative, systemic chemotherapy remains the 
cornerstone for the management of patients with metastatic 
disease or nonoperable locally advanced disease. It reduces 
cancer-related symptoms, and improves quality of life and 
survival in patients with advanced NSCLC.2,3 Although the 
first-line treatment of advanced NSCLC has evolved signifi-
cantly over the past decade, currently doublets of second- and 
third-generation of chemotherapy regimens seem to reach a 
plateau with response rates of 30% to 40%, median survival 
of 8 to 9 months and a 1-year survival rate of 35% to 40%.2–4 
There is a need to identify novel targets and treatment strate-
gies to improve the therapy for NSCLC patients.
Angiogenesis or new blood vessel formation is an 
important hallmark of many tumors. The vascular endothe-
lial growth factor (VEGF) plays an important role in the 
growth and metastasis of many cancers, including NSCLC.5 
Bevacizumab (Genenetech, South San Francisco, CA) is a 
recombinant humanized anti-VEGF monoclonal antibody that 
is approved for the treatment of metastatic colon and lung can-
cers. In randomized phase-III studies, the addition of bevaci-
zumab to standard chemotherapy improved both the response 
rate and survival in patients with advanced nonsquamous 
NSCLC.6,7 on the basis of the Eastern Cooperative oncology 
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(ECoG) 4599 trial, the combination of carboplatin, paclitaxel, 
and bevacizumab is a widely adopted frontline regimen in 
patients with advanced NSCLC.5,8
The ubiquitin-proteasome pathway plays a pivotal role 
in the degradation of most intracellular proteins in eukaryotic 
cells, including those regulating apoptosis, cell-cycle pro-
gression, transcription-factor activation, and angiogenesis.9,10 
Bortezomib (VELCADE; Millennium Pharmaceuticals, Inc., 
Cambridge, MA), a dipeptide proteasome inhibitor, is a novel 
antineoplastic agent presently approved for the treatment of 
patients with multiple myeloma and relapsed mantle-cell 
lymphoma.11,12 Bortezomib has been shown to have signifi-
cant cytotoxic activity in human NSCLC cell lines in vitro. 
Bortezomib induced concentration and time-dependent G2/M 
cell-cycle arrest of NSCLC cells.13–15 This G2/M arrest was 
unique and different from taxanes and vinca alkaloids, and 
does not involve tubulin.13,14 Bortezomib also induces apopto-
sis in cells that overexpress bcl-2, a genetic trait that confers 
unregulated growth and resistance to conventional chemother-
apeutics.16 Bortezomib has also been shown to have signifi-
cant antiangiogenic activity.25,26
In vivo activity was also observed in NSCLC xeno-
grafts and human NSCLC heterotransplant models (unpub-
lished data). Clinical activity was also observed in patients 
with refractory NSCLC in phase-I and -I trials.17,20 Because 
of its unique properties and single-agent activity we planned 
to do a pilot trial of combination of carboplatin, bortezomib 
and bevacizumab as first-line therapy in patients with meta-
static NSCLC. The rationale at the inception of the study was 
to substitute paclitaxel in the ECoG 4599 regimen by borte-
zomib because of its ability to induce unique G2/M cell-cycle 
arrest, as seen in preclinical studies.
The present study was designed as a phase-I/II study. 
The primary objective of the phase-I study was to define the 
maximum tolerated dose (MTD) of weekly bortezomib in 
combination with fixed standard doses of carboplatin and 
bevacizumab. The primary objective of the phase-II study was 
to estimate the efficacy (response rate and progression free 
survival [PFS]) and safety of combination therapy with car-
boplatin, bortezomib, and bevacizumab as first-line therapy in 
patients with advanced NSCLC. The study was closed early 
because of poor accrual. We will present the final safety and 
efficacy data from all 16 patients that were treated during the 
phase-I and -II portion of the study.
PATIENTS AND METHODS
Patients
Adult patients with inoperable, locally advanced, or 
metastatic NSCLC (stage IIIB with pleural effusion or stage-
IV disease, based on the 6th edition of the American Joint 
Committee on Cancer) were eligible for this study. Tumors 
were cytologically or histologically confirmed. As a result of 
safety concerns with bevacizumab, the study initially included 
only nonsquamous NSCLC patients. However, the study was 
subsequently amended to include patients with squamous cell 
histology if they met the following criteria: (1) extra-thoracic 
disease only (2) peripheral lung lesions only (peripheral lesion 
is defined as a lesion in which epicenter of tumor is less than 
2 cm from costal or diaphragmatic pleura and is more than 
2 cm from trachea, main and lobar bronchi). No squamous-
cell patients were accrued on the study at the time of study 
closure.
other key eligibility criteria included measurable dis-
ease, age 18 years or more, ECoG performance status of 2 
or lesser, no gross hemoptysis (defined as bright red blood 
of half-teaspoon or more), no history of thrombotic, hemor-
rhagic, or coagulopathy disorders, free of active infection, 
and availability for active follow-up. Patients also had to meet 
the key laboratory criteria, including a white blood cell count 
of more than 3500/mm3 and absolute neutrophil count more 
than 1500/mm3 and a platelet count of more than 100,000/ 
mm3; total bilirubin less than 1.5 mg/dl, creatinine less than 
1.5 mg/dl, or calculated creatinine clearance more than 45 ml/
min; international normalized ratio less than 1.5, and a partial 
thromboplastin time no greater than upper limits of normal 
within 1 week before registration. Patients with lung cancer, 
who were placed on anticoagulant therapy for a thrombotic 
event were not eligible for this study.
Patients must have received no prior chemotherapy for 
metastatic disease. Patient may have received chemotherapy 
in adjuvant setting or with radiation for stage-III disease. 
However, the disease-free interval from last chemotherapy 
had to be more than 6 months. Patients must be disease free 
for more than 5 years if they had a prior second malignancy, 
and had to agree to use an acceptable method of contraception 
for the duration of the study.
Patients meeting any of the following exclusion criteria 
were not enrolled in the study: untreated central nervous system 
disease with the exception of treated brain metastasis; a history 
of grade-2 or higher peripheral neuropathy within 14 days before 
enrollment; known previous sensitivity reactions to boron, or 
mannitol; known HIV positivity; myocardial infarction within 
6 months before enrollment or New york Hospital Association 
Class III or IV heart failure, uncontrolled angina, severe uncon-
trolled ventricular arrhythmias, or electrocardiographic evidence 
of acute ischemia or active conduction system abnormalities; 
inadequately controlled hypertension (defined as systolic blood 
pressure >150 mmHg and/or diastolic blood pressure of >100 
mmHg); history of stroke or transient ischemia attack or signifi-
cant vascular disease (e.g., aortic aneurysm requiring surgical 
repair or recent peripheral arterial thrombosis) within 6 months 
before day 1; major surgical procedure, open biopsy, or signifi-
cant traumatic injury within 28 days before day 1, anticipation 
of the need for major surgical procedure during the course of 
the study; minor surgical procedure such as fine-needle aspi-
rations or core biopsies (excluding the placement of vascular 
access device) within 7 days before day 1; proteinuria as demon-
strated by urine protein: creatinine ratio more than 1.0 at screen-
ing; history of abdominal fistula, gastrointestinal perforation, or 
intraabdominal abscess within 6 months before day 1; serious, 
nonhealing wound, ulcer, or bone fracture; receipt of other inves-
tigational drugs by the patient within 14 days before enrollment 
or expected participation in an experimental drug study during 
this study treatment; or serious medical or psychiatric illness 
likely to interfere with participation in this clinical study.
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The study was reviewed and approved by the institu-
tional review board of the University of Massachusetts and 
voluntary written informed consent from the patients was 
obtained before performance of any study-related procedure 
not part of normal medical care.
Study Design
The study was designed as a phase-I/II study to evalu-
ate the efficacy and safety of combination chemotherapy with 
carboplatin, bortezomib, and bevacizumab in patients with 
advanced NSCLC.
During the phase-I portion of the study, three dose lev-
els of weekly bortezomib were studied in conjunction with 
fixed-dose carboplatin and bevacizumab on a 21-day cycle to 
define the MTD. A maximum of six cycles was administered. 
Patients with complete response, partial response (PR), or 
stable disease after six cycles were allowed to continue on sin-
gle-agent bevacizumab every 3 weeks as maintenance therapy 
until disease progression.
Dose-limiting toxicity (DLT) was defined as: grade-4 
neutropenia or thrombocytopenia, any nonhematologic tox-
icity greater than grade 3 except alopecia or inadequately 
treated nausea or vomiting, neurosensory toxicity of grade 2 
with pain or any neurotoxicity greater than grade 2 during the 
first cycle of treatment.
During phase I, a traditional dose-escalation model was 
used. If no DLT was observed in three patients during the 
first cycle, the next dose level was accrued. If one DLT was 
observed, three additional patients were accrued to the dose 
level. If no additional DLTs were observed, the next dose level 
was accrued. However, if two or more DLTs were observed in 
a given dose level, one dose level below was to be defined as 
the MTD.
The following three preplanned three dose levels of 
weekly bortezomib (day 1 and day 8) were studied with fixed 
doses of carboplatin AUC 6, bevacizumab 15 mg/kg on day 1 
of every 21-day cycle: level I: 1.3 mg/m2; level II: 1.6 mg/m2, 
and level III 1.8 mg/m2. In phase II, either level III or MTD 
was administered in the same 21-day cycle to evaluate the effi-
cacy and safety of the regimen in the first-line treatment of 
advanced NSCLC.
Drug Administration
Bortezomib was supplied as a sterile lyophilized powder 
for reconstitution in vials containing bortezomib and mannitol 
at a 1:10 ratio. Bortezomib was administered as an intrave-
nous push over 3 to 5 seconds followed by a standard saline 
flush, or through a running intravenous line after carbopla-
tin infusion on day 1 and bortezomib alone on day 8 of each 
cycle. The dose of bortezomib was determined on the basis of 
body surface area.
Bevacizumab was supplied as a clear-to-slightly opal-
escent, colorless-to-pale brown sterile, liquid concentrate for 
solution for intravenous infusion. Bevacizumab was adminis-
tered as an intravenous infusion on day 1 of each cycle. The 
dose of bevacizumab was based on actual body weight on day 1, 
cycle 1 of treatment. Unless there is a significant change (e.g., 
loss or gain of >10% of the body weight), the dose remained the 
same in subsequent cycles. The initial dose was delivered over 
9015 minutes. If the first infusion was tolerated, the second 
infusion was delivered over 6010 minutes, and all subsequent 
infusions were delivered over 3010 minutes.
Carboplatin is commercially available and supplied as a 
sterile lyophilized powder in single-dose vials, and was admin-
istered as an intravenous infusion over 30 minutes after beva-
cizumab infusion on day 1 of each cycle. Carboplatin dosage 
was calculated for a target AUC 6 using the Calvert formula. 
The drugs were administered in the following order: bevaci-
zumab followed by carboplatin followed by bortezomib.
Before each drug dose, the patients were evaluated for 
possible toxicities that may have occurred after the previous 
dose(s). Toxicities were assessed according to the National 
Cancer Institute Common Terminology Criteria for Adverse 
Events, Version 3.0. Patients were required to have ANC more 
than 1500 and platelets more than 100,000 before day 1 of each 
cycle. For grade-3 or greater nonhematologic toxicities, study 
drugs were held for up to 2 weeks until the toxicity returned to 
grade 1 or better. on day 8, bortezomib was held if ANC was 
less than 1000 or platelet count was less than 100,000. The 
patient received one dose level lower of bortezomib if ANC 
was between 1000 and 1500 and the platelet count was higher 
than 100,000, and received a full dose if ANC was more than 
1000 and the platelet count was more than 100,000. If, after the 
study drugs were held, the toxicity did not resolve, as defined 
above, then the patient was discontinued from the protocol 
therapy. A treatment cycle delay or interruption of more than 
4 weeks because of toxicity resulted in removal of the patient 
from the study. If a treatment cycle was delayed because of 
hematological toxicity, all three agents including bevacizumab 
were held. If dose reduction was required for bortezomib on 
day 8 of a particular cycle, the lowest prior dose level was used 
on both day 1 and day 8 of the subsequent cycles.
The antiemetic regimen consisted of dexamethasone 
20 mg intravenous on day 1, and ondansetron 8 mg intrave-
nous on day 1 and ondansteron 8 mg oral or intravenous on 
day 8. Patients were allowed to receive full supportive care, 
including transfusions of blood and blood products, erythro-
poietin, antibiotics, and antiemetics when appropriate.
Patient Evaluation
Patients enrolled in this study were evaluated clinically 
and with standard laboratory tests before and at regular inter-
vals during their participation in this study. Safety evaluations 
consisted of medical interviews, recording of adverse events, 
physical examinations, blood pressure, and laboratory measure-
ments. Patients were evaluated for adverse events (all grades), 
serious adverse events, and adverse events requiring study 
drug interruption or discontinuation at each study visit for the 
duration of their participation in the study. During cycle 1, all 
patients were monitored on a weekly basis with physical exami-
nation, blood count, vital signs, and toxicity evaluation.
The patient’s target and nontarget lesions were mea-
sured by conventional techniques, and the overall disease 
response was assessed according to the Response Evaluation 
Criteria In Solid Tumors criteria every two cycles, starting 
with cycle 2.32
1035Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume  7, Number 6, June 2012 Bortezomib, Carboplatin, and Bevacizumab in NSCLC
An end-of-therapy visit was conducted 10 days after 
administration of the last dose of the study drug, and an end-
of-study visit was conducted 6 weeks after the end of therapy 
visit or last chemotherapy cycle. Safety and efficacy evalua-
tions were performed during these visits. Patients were fol-
lowed at least every 3 months for 2 years after the last dose of 
protocol therapy visit to evaluate the long-term toxicity and 
the survival data.
Biomarker Evaluation
Recent studies have identified the driver mutations in a 
subset of patients with NSCLC with adenocarcinoma histol-
ogy.19 The mutations in the epidermal growth factor receptor 
(EGFR) and k-ras oncogene, and the translocation in echi-
noderm microtubule-associated-protein-like (eml)/anaplastic 
lymphoma kinase (alk) fusion protein can have a significant 
impact on the outcome of patients in the lung cancer thera-
peutic trials. Data were collected on the molecular mutations 
for Kristne rat sarcoma oncogene (k-ras), EGFR and eml/alk 
translocations in our patients. The purpose was to correlate 
this data with the clinical outcomes, including response rate 
and survival, and to see whether there was any hint of activ-
ity of this regimen in any particular subgroup. The tests were 
performed as part of routine clinical practice at our institution. 
The tests were performed on formalin fixed, paraffin-embed-
ded blocks or recut sections from the block prepared on slides 
including one stained with hematoxylin and eosin. EGFR-
mutation and k-ras-mutation analysis were done by the molec-
ular pathology department at University of Massachusetts.
STATISTICAL METHOD AND ANALYSIS
The study was designed as a phase-I/II study. In the 
phase-I portion, the traditional dose-escalation model was 
used, and it was anticipated that nine to 18 patients would be 
enrolled. The phase-II portion was designed based on the opti-
mal two-stage phase-II study by Simons et al.31 The efficacy of 
the combination chemotherapy was designed to be evaluated 
by response rate.
The study was designed to test the null hypothesis that 
the response rate is 15% or less versus the alternative hypoth-
esis that the response rate is at least 30%. The response rate 
from carboplatin, paclitaxel, and bevacizumab in the E4599 
study was 27%. our hypothesis was that if we could achieve a 
similar response rate with a better tolerated regimen, it would 
be worthwhile to pursue this combination in a larger random-
ized study. Nineteen patients were planned to be accrued 
in the first stage of phase II. If three or fewer responses 
were observed during the first stage then the treatment was 
to be concluded early for lack of efficacy. otherwise, 36 
additional patients were accrued for the second stage. If 12 
or fewer responses among 55 patients were observed by the 
end of this phase-II study, no further investigation of this 
treatment regimen would be warranted. The power under this 
design is 80% and the type-I error is 0.05. The probability of 
early stopping at the first stage is 68.4% if the true response 
rate is 15%. If the true response rate is 30%, the probability 
of early stopping at the first stage is 13.3%. The study was 
stopped early because of poor accrual. There were only nine 
patients in the phase-II portion of the study at the time of 
study closure.
Descriptive statistics were used for baseline characteris-
tics and safety assessment. The response rate was calculated for 
all evaluable patients along with the 95% confidence interval 
(95% CI). The PFS and overall survival (oS) was calculated 
using the Kaplan-Meier method, along with their 95% CI.
RESULTS
Patient Population
A total of 16 patients with advanced NSCLC were 
enrolled between February 2007 and october 2010. All 
patients were included in the safety and efficacy analyses, and 
received at least one dose of the study drug. Table 1 shows 
the baseline characteristics of all patients. The majority of the 
patients (n = 11; 69%) had adenocarcinoma as histology; four 
patients with poorly differentiated NSCLC and one patient 
with adenocarcinoma with bronchoalveolar features. Fourteen 
patients (88%) were current or former smokers, and none of 
the patients had prior adjuvant chemotherapy. Thirteen patients 
(81%) had metastatic disease and the rest had stage IIIB with 
pleural effusion.
Treatment and Follow-Up
Sixteen patients received a total of 74 cycles of com-
bination of bortezomib, bevacizumab, and carboplatin. The 
number of patients treated at dose levels I, II, and III are three, 
four, and nine patients, respectively. one patient at dose level 
II was found to be ineligible because of preexisting peripheral 
vascular disease on retrospective review, and one additional 
patient (hence a total of four patients) was treated at level II. 
TABLE 1. Patient Demographics and Clinical 
Characteristics (N = 16)
Characteristic
No. of Patients  
(N = 16) %
Age, yrs
 Median (range) 63 (47–73)
Sex
 Female 7 44
ECoG PS
 0
 1
 2
 Unknown
2
10
2
2
12.5
62.5
12.5
12.5
Histology
 Adenocarcinoma
 Adenocarcinoma with BAC feature
 Poorly differentiated NSCLC
11
1
4
69
6
25
Smoking Hx
 Smoker
 Nonsmoker
14
2
88
12
Stage
 IIIB(effusion)
 IV
3
13
19
81
Prior adjuvant chemotherapy 0 0
ECoG, Eastern Cooperative oncology Group; BAC, bronchoalveolar carcinoma; 
NSCLC, non–small-cell lung cancer.
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There was no predefined DLT in any of the 16 patients in the 
cycle 1 of treatment. The recommended phase-II dose is bort-
ezomib 1.8 mg/m2 weekly on day 1 and day 8 in combina-
tion with carboplatin AUC of 6 and bevacizumab 15 mg/kg 
on every 21-day cycle. overall, nine patients were treated at 
the recommended phase-II dose level till the study was closed 
because of poor accrual.
The median follow-up was 9.1 months. Eight patients 
(50%) completed all six cycles of combination therapy and six 
patients continued on maintenance bevacizumab therapy. The 
main reason for discontinuation of therapy was disease progres-
sion (n = 11 patients; 69%). one patient at dose level II came off 
the study because of worsening of preexisting peripheral vascular 
disease; one patient because of intolerable toxicity (peripheral 
neuropathy and unexplained pain syndrome in sacral area) after 
cycle 5, and one patient died during the study because of rapid 
progression of the disease and general deterioration of clinical 
condition after cycle 3. Two patients are undergoing treatment on 
maintenance bevacizumab at the time of the report.
All the patients received planned full doses of carbo-
platin and bevacizumab. The dose reduction/ delay occurred 
in 50% of the patients. A total of 12 cycles of combination 
therapy was administered in three patients at cohort level I 
(bortezomib 1.3 mg/m2). There was no dose delay or reduction 
in any patient. At dose level II (bortezomib 1.6 mg/m2), four 
patients received a total of 20 cycles of combination therapy. 
Two patients required dose reduction in bortezomib at cycle 
4 because of thrombocytopenia. Totally 9 patients in cohort 
III (bortezomib 1.8mg/m2) received 42 cycles of combination 
of bortezomib, carboplatin, and bevacizumab. Five patients 
require dose delay/reduction in dose of bortezomib. The major 
cause of dose/delay or reduction is because of thrombocytope-
nia and usually in cycle 5 or 6.
Toxicity
Toxicity was defined as an adverse event considered pos-
sibly, probably, or definitely related to treatment. Toxicity was 
assessed according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events, Version 3.0. The 
combination of bortezomib, carboplatin, and bevacizumab 
was generally very well tolerated.
Common treatment-related adverse events occurring 
throughout the trial are summarized in Table 2. There was 
no dose-limiting toxicity in cycle 1 in all 16 patients treated. 
The predominant hematological toxicity included thrombo-
cytopenia and neutropenia. Grade-3 thrombocytopenia and 
neutropenia were common at the recommended phase-II dose 
of bortezomib1.8 mg/m2 and usually occured after cycle 4. 
None of the patients had neutropenic fever. one patient each 
required platelet and packed red-cell infusion. None of the 
patients required growth-factor support (or erythropoietin).
The common nonhematologic toxicities involving more 
than 30% of the patients include fatigue, anorexia, nausea, 
vomiting, diarrhea, and hyponatremia. The majority of these 
toxicities were grade 1 or 2. At the dose level III, one patient 
developed grade-3 diarrhea and dehydration, requiring a dose 
reduction. Another patient developed herpes zoster reacti-
vation involving face and cornea, most probably related to 
bortezomib. She was treated with acyclovir, and continued on 
acyclovir prophylaxis throughout the rest of the treatment.
Grade-1 or -2 peripheral neuropathy was observed in 
seven out of 16 patients (43%). only one patient discontinued 
treatment because of peripheral neuropathy and unexplained 
pain syndrome.
Two patients discontinued the treatment because of 
toxicity. one patient had worsening of existing peripheral 
vascular disease, and in retrospect did not meet the eligibil-
ity criteria. Another patient at dose level III discontinued the 
treatment because of peripheral neuropathy and unexplained 
pain syndrome, as mentioned previously.
Tumor Response and Survival
All 16 patients were evaluable for tumor response. 
There was no complete response; six patients had PR, making 
the overall response rate of 37.5 % (95% CI: 13.8–61.2). out 
of nine patients at dose level III, four patients (44%; 95% CI: 
15.3–77.3) had PR. The disease control rate (PR+SD) at the 
fourth month was 50%.
The median follow-up was 9.1 months. The PFS and oS 
of all the patients were 5.0 months (95%CI: 3.1–8.4) and 9.9 
months (95%CI: 8.2–14.1), respectively. The study included 
patients with a performance status of 2. The median PFS and 
oS in 13 patients with PS of 0 through 1 were 5.5 months 
(95%CI: 3.2–12.2) and 10.9 months (95% CI: 8.2–34.1), 
respectively.
TABLE 2. Treatment Related Adverse Events (N = 16)
Toxicity
Cycle 1
Grade 1/2
N (%)
Cycle 1
Grade 3/4
N (%)
All cycles
Grade 1/2
N (%)
All cycles
Grade 3/4
N (%)
Hematological
 Anemia 7 (44) 0 14 (88) 1 (6)
 Thrombocytopenia 4 (25) 1 (8) 10 (62) 7 (58)
 Neutropenia 2 (12) 0 8 (50) 2 (12)
 Lymphopenia 1 (6) 0 9 (56) 4 (25)
Nonhematological
 Fatigue 5 (31) 0 10 (62) 2 (12)
 Anorexia 4 (25) 0 7 (44) 2 (12)
 Nausea 9 (56) 0 11 (69) 3 (19)
 Vomiting 1 (6) 0 5 (31) 3 (19)
 Diarrhea 5 (31) 0 9 (56) 4 (25)
 Constipation 3 (19) 0 7 (44) 0
 Pain 5 (31) 1 (6) 6 (38) 1 (6)
 Dehydration 1 (6) 0 5 (31) 2 (12)
 Hypertension 1 (6) 2 (12) 2 (12) 2 (12)
 Hemorrhage 3 (25) 0 9 (56) 0
  Hemorrhage 
 (pulmonary)
0 0 0 1 (6)
 Thrombosis 0 0 1 (6) 1 (6)
 Hyponatremia 10 (62) 1 (8) 12 (75) 0
 Hyperglycemia 5 (32) 0 9 (56) 0
 Hypomagnesemia 0 0 5 (31) 0
 Neuropathy 0 0 7 (44) 0
 Infections 2 (12) 0 4 (25) 2 (12)
CTC version AE 3.0.
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There were a total of nine patients treated at dose level 
III (the recommended phase-II dose). The study was closed 
prematurely because of poor accrual. The overall response 
rate in this group is 44% (95%CI: 15.3–77.3). This cohort of 
patients had a median PFS of 5.5 months (95%CI: 3.1, 12.2) 
and oS of 10.9 months (95%CI: 8.0–14.1)
Biomarker Data
Recent studies have shown that a subset of patients hav-
ing NSCLC with adenocarcinoma histology carries driver 
mutations that can have a significant impact on prognosis and 
response to different targeted therapies.19 EGFR mutation is 
present in 15% to 20% of adenocarinoma, and is associated 
with better prognosis and response to EGFR tyrosine kinase 
inhibitors. The k-ras mutation is reported in 20% to 30% of 
adenocarcinoma, and is associated with poor prognosis. EML/
alk translocation is present in 4% of adenocarcinoma, and has 
been associated with response to crizotinib.19
We collected the mutation data from our patients in the 
current study. Thirteen patients had k-ras mutation testing, 
and four (30%) have mutations in k-ras oncogene. out of six 
patients with PR to the combination regimen five patients had 
wild-type k-ras, and one patient had k-ras mutation.
EGFR mutation status was available in 13 patients, and 
all the patients had wild-type EGFR. one patient on the study 
was subsequently found to have eml/alk translocation. This 
patient had PR to the combination of carboplatin, bortezomib, 
and bevacizumab, and had the PFS of 12 months. He subse-
quently was treated with crizotinib on a clinical trial, and had 
prolonged disease control. Although this is clearly anecdotal, 
we found it interesting to have a very good PR and prolong 
PFS with a combination of carboplatin, bortezomib, and beva-
cizumab in this particular patient.
DISCUSSION
Bortezomib is a novel proteasome inhibitor that has shown 
interesting preclinical and clinical activity in NSCLC.13–17 
In this study, we examined the combination of bortezomib 
with carboplatin and bevacizumab. We used weekly dosing of 
bortezomib in combination with standard doses of carboplatin 
and bevacizumab. The study was designed as a phase-I/II study 
with the primary aim of phase-I portion of the study being the 
determination of the MTD of bortezomib that can be adminis-
tered with standard doses of carboplatin and bevacizumab.
The combination of bortezomib, carboplatin, and beva-
cizumab was generally very well tolerated. We did not notice 
any dose limiting toxicity during the first cycle in all 16 
patients treated. our recommended phase-II dose level is bort-
ezomib 1.8 mg/m2 on day 1 and day 8 with standard doses of 
carboplatin (AUC of 6) and bevacizumab (15 mg/kg). At this 
dose level, increased hematological toxicity, particularly neu-
tropenia and thrombocytopenia, was seen in patients receiving 
more than four cycles. This required dose delays, but four out 
of nine patients completed all planned six cycles of chemo-
therapy. The major reason for discontinuation of treatment 
was disease progression, and only one patient come off the 
study because of intolerable toxicity, and this was not a result 
of hematological toxicity.
The peripheral neuropathy was one of the known 
side effects of bortezomib.11,12 Among the patients in our 
study, 43% developed grade-I/II peripheral neuropathy. one 
patient at dose level III had an unusual painful syndrome 
TABLE 3. Results for Known Genetic Mutations, Response, PFS, and OS (N = 16)
Patient ID Dose Level
EGFR 
Mutation
K-ras 
Mutation
EML/alk 
Translocation No. of Cycles Response PFS (months) OS (months)
01 1 n/a n/a n/a 6 SD 4.6 8.4
02 1 n/a n/a n/a 4 SD 2.4 7.6
03 1 wild pos n/a 2 PD 1.2 3.7
04 2 wild wild pos 15* PR 12.2 33.6
05 2 wild wild n/a 2 SD 1.5 9.5
06 2 wild pos n/a 6 SD 3.8 8.1
07 2 wild wild n/a 8* PR 8.3 26.7+
08 3 wild pos n/a 5 PR 9.2 12
09 3 wild wild n/a 3 SD 2.1 2.1
10 3 n/a n/a n/a 2 PD 1.1 9.8
11 3 wild wild n/a 8* PR 6.5 21.1+
12 3 wild wild n/a 4 SD 2.7 13.9
13 3 wild wild n/a 10 PR 5.4 10.8
14 3 wild wild n/a 4 SD 3.2 7.8
15 3 wild wild n/a 11*† PR 9.0+ 9.0+
16 3 wild pos n/a 9*† SD 7.0+ 7.0+
* Patients continued on single-agent bevacizumab after six cycles.
† Undergoing active treatment.
+ Alive in follow-up.
EGFR, epidermal growth factor receptor; K-ras, Kristen rat sarcoma oncogene; EML, echinoderm microtubule-associated-protein-like; alk, anaplastic lymphoma 
kinase; PFS, progression-free survival; oS, overall survival; n/a, not available; SD, stable disease; PD, progressive disease; PR, partial response; pos, positive. 
Bold text indicates patients with partial response to treatment.
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FIGURE 1. Computed tomography 
scans showing partial responses.  
A, Lung nodule in patient #8  
prechemotherapy; (B) post two 
cycles; (C) hilar mass and malig-
nant pleural effusion in patient #11 
prechemotherapy; and (D) post four 
cycles, marked reduction in hilar 
mass and complete resolution of 
malignant pleural effusion.
FIGURE 2. Kaplan-Meier plots for (A) PFS of all patients; (B) OS of all patients; and (C) PFS and OS of patients treated in 
cohort 3 (recommended phase-II dose). PFS, progression-free survival; OS, overall survival.
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and stopped treatment after five cycles. Painful grade-II sen-
sory neuropathy or grade-III peripheral neuropathy was not 
observed. This may be because of the fact that we used a 
weekly regimen and the bortezomib was limited to six cycles 
with chemotherapy.
The primary end point of the phase-II portion of the 
study was to estimate the response rate and PFS. The study was 
closed prematurely because of poor accrual, and is underpow-
ered to definitely estimate the response rate and PFS. Four out 
of 9 patients at the recommended phase-II dose level received 
partial remission with a median PFS and oS of 5.5 months 
and 10.9 months, respectively. This exceeded our preplanned 
response rate of 30% or three out of the initial planned 19 
patients in the first stage of phase-II portion of the study. our 
response rate from bortezomib, carboplatin, and bevacizumab 
seems to be comparable with bevacizumab in combination with 
other standard doublet chemotherapies (carboplatin/paclitaxel 
or gemcitabine/cisplatin or carboplatin/permetrexed).6,7 The 
number of patients in the phase-II portion of this study is very 
small, and the study is underpowered to draw any definite con-
clusion regarding the survival data and efficacy of this regi-
men. Regardless of this, the regimen was very well tolerated 
with interesting activity. A larger randomized phase-II study 
with the standard doublet with bevacizumab as control arm 
will further define the activity of this regimen.
Bortezomib has been extensively studied in the treat-
ment of metastatic NSCLC with mixed results.17–24 The stan-
dard dose of bortezomib 1.3 mg/m2 twice a week had limited 
single-agent activity in patients with advanced NSCLC.18 In 
a multicenter phase-II study, the addition of bortezomib to 
gemcitabine and carboplatin had shown interesting activity 
and survival.21 However, in other randomized phase-II studies, 
the addition of bortezomib to single agent docetaxel, peme-
trexed, or erlotinib offered no statistically significant response 
or survival advantage.22–24 our study is the first to evaluate the 
combination of bortezomib with chemotherapy and a bevaci-
zumab-based regimen.
There is considerable interest to combine different tar-
geted therapies. In preclinical models, bortezomib has been 
shown to have antiangiogenic effects via direct or indirect 
effects on endothelial cells.25 In multiple myeloma-derived 
endothelial cells, bortezomib triggered a dose-dependent inhi-
bition of the VEGF and interleukin-6 secretion, and induced 
downregulation of VEGF, interleukin-6, insulin-like growth 
factor-I, Angiopoietin 1, and Angiopoietin 2 transcription.25 
Bortezomib has also been shown to induce the autophagic 
death of proliferating endothelial cells.26
Recent studies have shown increased levels of VEGF 
and other proangiogenic factors in patients treated with 
bevacizumab.27,28 VEGF feedback production in response to 
bevacizumab therapy was shown to be entirely host derived 
and tumor independent.29 High posttreatment plasma VEGF 
levels have been associated with poorer outcome in NSCLC 
patients treated with bevacizumab.28 Bortezomib has been 
shown to augment the activity of bevacizumab by modulat-
ing hypoxia-inducible factor-1 transcription and subsequent 
proangiogenic factor production. In a phase-I study, the com-
bination of bortezomib and bevacizumab was well toler-
ated and the pharmacodynamic studies showed significant 
decrease in levels of proangiogenic factors, including VEGF 
levels.30 When we designed this trial, we decided only to con-
tinue single-agent bevacizumab as maintenance therapy after 
six cycles of the combination therapy on the basis of an initial 
ECoG study of bevacizumab in combination with carboplatin 
and paclitaxel. The majority of the patients who finished the 
planned six cycles of chemotherapy and received single-agent 
bevacizumab progressed on single-agent bevacizumab. It will 
be interesting in future trials to examine the role of bortezomib 
and bevacizumab maintenance therapy after initial induction 
chemotherapy with a platinum-based regimen or the current 
combination regimen.
In summary, the combination of weekly bortezomib 
with standard doses of carboplatin and bevacizumab is very 
well tolerated in patients with advanced NSCLC. The recom-
mended phase-II dose is bortezomib 1.8 mg/m2 on day 1 and 
day 8 in combination with carboplatin AUC of 6 and bevaci-
zumab 15 mg/kg on day 1 every three weeks. Interesting clini-
cal activity was observed in patients with advanced NSCLC 
but this trial is underpowered to determine the general efficacy 
of the studied regimen.
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